65,437 trials
Knee Osteoarthritis
Primary: Change in Maximal Isokinetic Knee Extensor Torque by Body Mass Assessed by Isokinetic Dynamometer. — 0.06; 0.03 Newton-meters/kilogram — p=.67
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the Problem Areas in Diabetes (PAID) Child and Teen (C&T) Parent Questionnaire…
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 0 Participants
Attention Deficit Hyperactivity Disorder
Primary: Child Behavioral Functioning — 4.78; 4.56; 4.44; 4.67 units on a scale
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Friedreich's Ataxia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 78; 61; 4; 0 participants
Seasonal Allergic Rhinitis
Primary: Performance on Test of Variables of Attention (TOVA) - a Standardized Test of Cognitive Performance — 2.63; 3.95; 1.20; 1.83 number of errors
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Healthy
Primary: Number of Participants Reporting Adverse Events — 1; 2 Participants
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Acne Vulgaris
Primary: Absolute Change in Facial Inflammatory Lesion Counts at Week 12 — -15.3; -10.1 lesion count — p=< 0.0001
Contact Lens Discomfort · Dry Eye Disease · Meibomian Gland Dysfunction
Primary: Mean Change in the Duration of Subject-reported Comfortable Contact Lens Daily Wear Time (Hours Per Day) — 9.2; 8.5; 7.1 hours per day — p=0.02
Ureaplasma Infections
Primary: Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma — 37; 55 Participants — p=<0.0001
Hepatitis C
Primary: Sustained Viral Response — 13; 8 Participants